Some authors have proposed the use of the flu vaccine to reduce the severity of COVID-19 cases, while some have proposed the use of ACE Inhibitors (ACEI) or Angiotensin Receptor blockers (ARB), since this virus shares hemagglutinin as a transmission mechanism and acts on the ACE2 enzyme during infection. Other authors described how none of the elderly patients receiving antihistamines and azythromycin in two nursing homes in Toledo -Spain- during the first wave died or needed hospital admission, even considering that 100% of residents had a positive serological test after that wave. Other authors have described a positive evolution in patients receiving amantadine for their Parkinson's disease. The aim is to evaluate whether the admitted patients who are previously vaccinated or those who were already receiving these treatments showed a better evolution.
The number COVID cases would be related to hospital admissions. Among hospital admissions,
the number of previous treatments, the length of admission, the need or not of the Intensive
Care Unit (ICU) and their final status (survivors or non survivors) would be studied.
If patients that previously received the influenza vaccine or treated with ACEI, ARB,
antihistamines or amantadine showed a better evolution, it would be proposed to extend
vaccination and the inclusion of ACE inhibitors, ARB, antihistamines or amantadine in the
treatment of infection.
Drug: Antihistamine
No intervention is performed. We propose an observational study.
Other Name: Antihistamines for COVID
Drug: Amantadine
No intervention is performed. We propose an observational study
Other Name: Amantadine for COVID
Drug: ACEI
No intervention is performed. We propose an observational study.
Other Name: ACEI and COVID
Drug: ARB
No intervention is performed. We propose an observational study.
Other Name: ARB and COVID
Other: Influenza vaccine and COVID
No intervention is performed. We propose an observational study.
Inclusion Criteria:
- Hospital Admissions at the Hospital of Terrassa from March 1, 2020 for any cause.
Exclusion Criteria:
- None.
- For comparison of percentage of Influenza vaccination, ACEI and ARB vs general
population, patients from outside the reference area of the Terrassa Health Consortium
would be excluded.
Hospital de Terrassa
Terrassa, Barcelona, Spain
Investigator: Anna Puigdellívol-Sánchez, Ph.D.
Contact: 34-93-5884555
apuigdellivol@cst.cat
Anna Puigdellívol-Sánchez, Ph.D.
34-93-5884555
apuigdellivol@cst.cat
Mar Muñoz
34-93-7003657 - 1895
Reserca@cst.cat
Anna Puigdellívol-Sánchez, Ph D, Principal Investigator
Consorci Sanitari de Terrassa